23.94
23.94 (0%)
As of Feb 14, 2025
Cidara Therapeutics, Inc. [CDTX]
Source:
Company Overview
Cidara Therapeutics, Inc is a biotechnology company using our proprietary Cloudbreak platform to develop drug-Fc conjugate, or DFC, immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | 858-752-6170 |
| Industry | manufacturing |
| CEO | Jeffrey Stein, Ph.D. |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.3 |
| Operating Profit | $-176.1 |
| Net Income | $-169.8 |
| Net Cash | $160.4 |
Profit Ratios
| Gross Margin | $1.3 |
| Operating Margin | -13,811.9 |
| Profit as % of Revenues | -0.8% |
| Profit as % of Assets | -120.5% |
| Profit as % of Stockholder Equity | -104% |
Management Effectiveness
| Return on Equity | -104.3% |
| Return on Assets | -79.3% |
| Turnover Ratio | 0.9% |
| EBITA | $-176.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $214.8 |
| Total Liabilities | $51.5 |
| Operating Cash Flow | $-176.5 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $337.1 |
